Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikhil Amin

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Journal of Diabetes Science and Technology|November 4, 2009
Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetesCees J Tack, Vladimir Christov, Bastiaan E de Galan, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 24, 2018
Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthmaJonathan Corren, Mario Castro, Pascal Chanez, et al.
The Annals of Otology, Rhinology, and Laryngology|June 16, 2023
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study ResultsClaus Bachert, Tanya M Laidlaw, Seong H Cho, et al.
The Laryngoscope|November 24, 2021
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome ThresholdsChien-Chia Chuang, Isabelle Guillemin, Claus Bachert, et al.
Allergy|August 30, 2021
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trialsJoaquim Mullol, Tanya M Laidlaw, Claus Bachert, et al.
JAMA Dermatology|February 18, 2026
Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical TrialsThomas B Casale, Sarbjit S Saini, Moshe Ben-Shoshan, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 26, 2023
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitizationJonathan Corren, Nicola A Hanania, William W Busse, et al.
International Forum of Allergy & Rhinology|February 21, 2021
Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polypsClaire Hopkins, Martin Wagenmann, Claus Bachert, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 26, 2021
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseasesJennifer D Hamilton, Sivan Harel, Brian N Swanson, et al.
ERJ Open Research|February 4, 2020
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthmaMario Castro, Klaus F Rabe, Jonathan Corren, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Journal of Diabetes Science and Technology|November 4, 2009
Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetesCees J Tack, Vladimir Christov, Bastiaan E de Galan, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 24, 2018
Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthmaJonathan Corren, Mario Castro, Pascal Chanez, et al.
The Annals of Otology, Rhinology, and Laryngology|June 16, 2023
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study ResultsClaus Bachert, Tanya M Laidlaw, Seong H Cho, et al.
The Laryngoscope|November 24, 2021
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome ThresholdsChien-Chia Chuang, Isabelle Guillemin, Claus Bachert, et al.
Allergy|August 30, 2021
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trialsJoaquim Mullol, Tanya M Laidlaw, Claus Bachert, et al.
JAMA Dermatology|February 18, 2026
Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical TrialsThomas B Casale, Sarbjit S Saini, Moshe Ben-Shoshan, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 26, 2023
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitizationJonathan Corren, Nicola A Hanania, William W Busse, et al.
International Forum of Allergy & Rhinology|February 21, 2021
Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polypsClaire Hopkins, Martin Wagenmann, Claus Bachert, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 26, 2021
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseasesJennifer D Hamilton, Sivan Harel, Brian N Swanson, et al.
ERJ Open Research|February 4, 2020
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthmaMario Castro, Klaus F Rabe, Jonathan Corren, et al.
Pageof 6